In SCLC, the available evidence suggests no apparent role of DDR alterations as predictors of response to treatment; however, the presence of surrogate non-DDR-related markers (such as SLFN11) could help select for patients responsive to PARP inhibition. Here, PARP1 is linked to small cell lung carcinoma.